<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8340">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034604</url>
  </required_header>
  <id_info>
    <org_study_id>2013-02-043</org_study_id>
    <nct_id>NCT02034604</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate efficacy and safety of naftopidil in patient with
      neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in patients' symptom questionnaires</measure>
    <time_frame>from baseline to 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>international prostate symptom score (IPSS) change, except QOL domain scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in uroflow parameters</measure>
    <time_frame>from baseline to 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>maximal flow rate, mean flow rate, voided volume and Changes in uroflowmetry parameters : maximal flow rate,mean flow rate, voided volume and PVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of patients showed an improvement in IPSS total scores of more than 25%.</measure>
    <time_frame>from baseline to 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit, Satisfaction, and Willingness to Continue (BSW) questions</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of global response assessment for Korean, GRA-K</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction question, TSQ</measure>
    <time_frame>8 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety evaluation : incidence and severity of adverse events</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in each domain scores of IPSS</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in number of urinary frequency, nocturia</measure>
    <time_frame>up to 8weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Neurogenic Lower Urinary Tract Dysfunction</condition>
  <arm_group>
    <arm_group_label>Naftopidil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naftopidil medication patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin Goup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin medication  patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftofidil</intervention_name>
    <arm_group_label>Naftopidil Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <arm_group_label>Tamsulosin Goup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 20 years old and above (upper limit of age: 80 years old)

          2. patients diagnosed as neurogenic bladder due to cerebrovascular accident, parkinson
             disease, spinal cord lesion, diabetic neuropathy etc)

          3. a+b

               1. IPSS ≥ 12 and QoL ≥ 3

               2. Maximum Flow Rate &lt;15 mL/s  (Voiding volume) ≥ 120mL)

          4. Ability and willingness to correctly complete the micturition diary and questionnaire

          5. Capable of understanding and having signed the informed consent form after full
             discussion of the research nature of the treatment and its risks and benefits

        Exclusion Criteria:

          1. In male aged 50 years old  and above, bladder outlet obstruction (Bladder Outlet
             Obstruction Index(BOOI) ≥40)

          2. In female, Pelvic Organ Prolapse ICS stage; POP-Q stage ≥ 2

          3. In female, the history of anti-incontinence operation.

          4. Patients with cancer of any type including cancer of the prostate or bladder

          5. Patients with urethral stricture or bladder neck contracture
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
    <phone>82-2-3410-3554</phone>
    <email>keleedr@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
      <phone>82-2-3410-3554</phone>
      <email>ksleedr@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Wook You, M.D.</last_name>
      <phone>82-2-3410-1268</phone>
      <email>khdoct29@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kyu-Sung Lee, Ph.D, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>professor,MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Naftopidil</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naftopidil</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
